Invesco
LXEO icon

Invesco’s Lexeo Therapeutics LXEO Stock Holding History

Invesco’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$365K Sell
63,518
-399,511
-86% -$2.83M ﹤0.01% 3269
2025
Q4 		$4.6M Buy
+463,029
New +$4.23M ﹤0.01% 2272

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's LXEO Position: Q1 2026 in Review

Invesco reduced its Lexeo Therapeutics (LXEO) stake by 86% in Q1 2026, selling an estimated $2.83M and leaving 63,518 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #3269.

Invesco first reported a position in LXEO in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.6M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Invesco held 63,518 shares of Lexeo Therapeutics worth $365K as of Q1 2026.
  • Invesco sold 399,511 Lexeo Therapeutics shares in Q1 2026, an estimated $2.83M.
  • Lexeo Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3269 holding.
  • Invesco first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Invesco's Lexeo Therapeutics position peaked at $4.6M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.